The collaboration will explore RNA-based small molecule drug candidates aimed at neurological conditions where existing ...

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...

Skyhawk's RNA tech could be Merck's next blockbuster play as drug setbacks and looming patent cliffs force a reinvention.

Merck KGaA agreed to collaborate with Skyhawk Therapeutics Inc. to develop neurological therapies in a deal that could be ...

Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since ...

Privately-held US biotech Skyhawk Therapeutics has announced a strategic research collaboration with Germany’s Merck KGaA ...

Adding another name to an impressive roster of partners assembled over the past few years, Skyhawk Therapeutics Inc. inked a ...

Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

Under the deal, Skyhawk was in line for around $600 million per program target, which came in the form of an undisclosed upfront cash payment and, if Merck exercises its option, potential opt-in ...

The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on ...

Merck & Co. and Skyhawk Therapeutics launch a collaboration that could pay the Waltham, MA, biotech approximately $600 million for every small molecule program the companies develop against ...

Skyhawk announced Monday that will earn up to $600 million in upfront and potential milestone payments for each molecule it develops for pharmaceutical giant Merck & Co. (NYSE: MRK).